Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07021209 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

GT719 Injection for Recurrent/Refractory Antibody-mediated Neurological Immune Diseases

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv4
  2. Enrollment target: 24 to 30v3 Show 5 more changesShow less
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site contact updated
    • Collaborators expanded, about 2 words
    • Study title shortened, about 1 word
  3. Eligibility criteria shortened, about 7 words
    • Study title shortened, about 3 words
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is an open-label, prospective, exploratory clinical trial that includes a dose escalation phase and a dose expansion phase, aimed at evaluating the safety, cell dynamics, and preliminary efficacy of GT719 cells in adult participants with recurrent/refractory antibody-mediated neurological immune diseases.
Trial Details
NCT Number NCT07021209
Lead Sponsor Grit Biotechnology
Collaborators: Tongji Hospital
Conditions
(from sponsor)		 Neurological Autoimmune Diseases
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov